Schizophrenia Research
Volume 75, Issue 1 , Pages 135-137 , 1 June 2005

Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up

  • John Stirling

      Affiliations

    • Department of Psychology and Speech Pathology, Manchester Metropolitan University, Elizabeth Gaskell Building, Hathersage Road, M13 0JA, UK
    • School of Psychiatry and Behavioural Sciences, University of Manchester, Wythenshawe Hospital, M23 9LT, UK
    • Corresponding Author InformationCorresponding author. Department of Psychology and Speech Pathology, Manchester Metropolitan University, Elizabeth Gaskell Building, Hathersage Road, M13 0JA, UK. Tel.: +44 161 247 2561; fax: +44 161 247 6364.
    • ,
  • Shon Lewis

      Affiliations

    • School of Psychiatry and Behavioural Sciences, University of Manchester, Wythenshawe Hospital, M23 9LT, UK
    • ,
  • Richard Hopkins

      Affiliations

    • School of Psychiatry and Behavioural Sciences, University of Manchester, Wythenshawe Hospital, M23 9LT, UK
    • ,
  • Colin White

      Affiliations

    • School of Psychiatry and Behavioural Sciences, University of Manchester, Wythenshawe Hospital, M23 9LT, UK

Received 23 August 2004 ,Revised 8 October 2004 ,Accepted 21 October 2004.

References 

  1. Arndt S, Tyrrell G, Flaum M, Andreasen NC. Comorbidity of substance abuse and schizophrenia: the role of pre-morbid adjustment. Psychol. Med. 1992;22:379–388
  2. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffit TE. Cannabis use in adolescence and risk for adult psychosis: a longitudinal prospective study. BMJ. 2002;325:1212–1213
  3. Cannon-Spoor HE, Potkin SG, Wyatt RJ. Measurement of pre-morbid adjustment in chronic schizophrenia. Schizophr. Bull. 1982;8(2):470–484
  4. Graham FK, Kendall BS. Memory for designs test: revised general manual. Percept. Mot. Skills. 1960;11:147–188
  5. Joyal CC, Halle P, Lapierre D, Hodgins S. Drug abuse and/or dependence and better neuropsychological performance in patients with schizophrenia. Schizophr. Res. 2003;63:297–299
  6. Kirkpatrick B, Amador XF, Flaum M, Yale SA, Gorman JM, Carpenter WT, et al. The deficit syndrome in the DSM IV field trial I: alcohol and other drug abuse. Schizophr. Res. 1996;20:69–77
  7. Meuser KT, Drake RE, Wallach MA. Dual diagnosis: a review of etiological theories. Addict. Behav. 1998;23:7171–7734
  8. Montague LR, Tantam D, Newby D, Thomas P, Ring N. The incidence of negative symptoms in early schizophrenia, mania and other psychoses. Acta Psychiatr. Scand. 1989;79:613–618
  9. Scheller-Guilkey G, Lewine RRJ, Brown CFW. Schizophrenia, substance abuse and brain morphology. Schizophr. Res. 1999;35:113–120
  10. Stirling J, White C, Hopkins R, Lewis S, Montague L, Huddy A. Onset predictors of clinical and functional outcome in individuals first diagnosed with a schizophrenic disorder 11–12 years ago. Schizophr. Res. 2002;49:162–163
  11. Stirling J, White C, Lewis S, Hopkins R, Tantam D, Huddy A, et al. Neurocognitive function and outcome in first episode schizophrenia: a 10 year follow-up of an epidemiological cohort. Schizophr. Res. 2003;65:75–86
  12. van Os J, Bak M, Hanssen M, Bijl RV, de Graff R, Verdoux H. Cannabis use and psychosis: a longitudinal population based study. Am. J. Epidemiol. 2002;156:319–327
  13. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self-report cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: a historical cohort. BMJ. 2002;325:1199–1204

PII: S0920-9964(04)00398-6

doi: 10.1016/j.schres.2004.10.006

Schizophrenia Research
Volume 75, Issue 1 , Pages 135-137 , 1 June 2005

Article Tools